Acorda Therapeutics (NASDAQ:ACOR) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Friday.

Several other brokerages also recently commented on ACOR. Cantor Fitzgerald assumed coverage on shares of Acorda Therapeutics in a report on Thursday, August 23rd. They issued a “neutral” rating and a $32.00 target price on the stock. Stifel Nicolaus lifted their target price on shares of Acorda Therapeutics from $15.00 to $25.00 and gave the stock a “hold” rating in a report on Tuesday, August 7th. BidaskClub upgraded shares of Acorda Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, August 7th. HC Wainwright set a $31.00 target price on shares of Acorda Therapeutics and gave the stock a “buy” rating in a report on Monday, August 6th. Finally, Oppenheimer set a $21.00 target price on shares of Acorda Therapeutics and gave the stock a “hold” rating in a report on Thursday, August 2nd. Eight investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $26.56.

Shares of ACOR opened at $19.78 on Friday. The firm has a market capitalization of $884.59 million, a P/E ratio of 19.02 and a beta of 1.49. Acorda Therapeutics has a one year low of $15.60 and a one year high of $36.35. The company has a current ratio of 4.03, a quick ratio of 3.95 and a debt-to-equity ratio of 0.57.

Acorda Therapeutics (NASDAQ:ACOR) last announced its earnings results on Wednesday, October 31st. The biopharmaceutical company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.02 by $0.15. The firm had revenue of $142.80 million for the quarter, compared to the consensus estimate of $82.74 million. Acorda Therapeutics had a negative net margin of 24.88% and a positive return on equity of 13.72%. The business’s quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.43 EPS. On average, research analysts expect that Acorda Therapeutics will post 0.08 EPS for the current fiscal year.

In other news, major shareholder Scopia Capital Management Lp sold 13,829 shares of the business’s stock in a transaction dated Thursday, September 6th. The shares were sold at an average price of $27.82, for a total transaction of $384,722.78. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders have sold 490,832 shares of company stock worth $9,121,364. Insiders own 7.80% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Xact Kapitalforvaltning AB increased its holdings in shares of Acorda Therapeutics by 20.7% during the 2nd quarter. Xact Kapitalforvaltning AB now owns 10,502 shares of the biopharmaceutical company’s stock worth $301,000 after purchasing an additional 1,800 shares during the period. NumerixS Investment Technologies Inc boosted its position in shares of Acorda Therapeutics by 123.5% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 3,800 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 2,100 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Acorda Therapeutics by 2.2% during the 2nd quarter. Rhumbline Advisers now owns 112,667 shares of the biopharmaceutical company’s stock valued at $3,234,000 after acquiring an additional 2,388 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Acorda Therapeutics by 2.9% during the 1st quarter. Legal & General Group Plc now owns 96,867 shares of the biopharmaceutical company’s stock valued at $2,293,000 after acquiring an additional 2,727 shares in the last quarter. Finally, Public Employees Retirement System of Ohio acquired a new stake in shares of Acorda Therapeutics during the 2nd quarter valued at about $132,000.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.

Featured Story: What is the 52-week high/low?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.